Recent innovations in head and neck oncology: a report from the ICHNO

Stoeckli, Sandro J.; Broglie, Martina A.

doi:10.1586/era.13.36

Cited by 4 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Innovative approaches for recurrent H&N cancer treatment are under evaluation in preclinical and clinical trials; among these, we include extracellular vesicles, thermal ablation/hyperthermia, gene therapy, and nano-immunotherapy as summarized in Figure 3 [ 11 , 48 , 49 , 50 , 51 , 52 ]. These treatment strategies can come as combined interventions to obtain a synergic and enhanced anticancer effect.…”

Section: Head-and-neck Cancersmentioning

confidence: 99%

Electroporation in Head-and-Neck Cancer: An Innovative Approach with Immunotherapy and Nanotechnology Combination

Pisani

Bertino

Prina-Mello

et al. 2022

Cancers

View full text Add to dashboard Cite

Squamous cell carcinoma is the most common malignancy that arises in the head-and-neck district. Traditional treatment could be insufficient in case of recurrent and/or metastatic cancers; for this reason, more selective and enhanced treatments are in evaluation in preclinical and clinical trials to increase in situ concentration of chemotherapy drugs promoting a selectively antineoplastic activity. Among all cancer treatment types (i.e., surgery, chemotherapy, radiotherapy), electroporation (EP) has emerged as a safe, less invasive, and effective approach for cancer treatment. Reversible EP, using an intensive electric stimulus (i.e., 1000 V/cm) applied for a short time (i.e., 100 μs), determines a localized electric field that temporarily permealizes the tumor cell membranes while maintaining high cell viability, promoting cytoplasm cell uptake of antineoplastic agents such as bleomycin and cisplatin (electrochemotherapy), calcium (Ca2+ electroporation), siRNA and plasmid DNA (gene electroporation). The higher intracellular concentration of antineoplastic agents enhances the antineoplastic activity and promotes controlled tumor cell death (apoptosis). As secondary effects, localized EP (i) reduces the capillary blood flow in tumor tissue (“vascular lock”), lowering drug washout, and (ii) stimulates the immune system acting against cancer cells. After years of preclinical development, electrochemotherapy (ECT), in combination with bleomycin or cisplatin, is currently one of the most effective treatments used for cutaneous metastases and primary skin and mucosal cancers that are not amenable to surgery. To reach this clinical evidence, in vitro and in vivo models were preclinically developed for evaluating the efficacy and safety of ECT on different tumor cell lines and animal models to optimize dose and administration routes of drugs, duration, and intensity of the electric field. Improvements in reversible EP efficacy are under evaluation for HNSCC treatment, where the focus is on the development of a combination treatment between EP-enhanced nanotechnology and immunotherapy strategies.

show abstract

Section: Head-and-neck Cancersmentioning

confidence: 99%

Electroporation in Head-and-Neck Cancer: An Innovative Approach with Immunotherapy and Nanotechnology Combination

Pisani

Bertino

Prina-Mello

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Aproximadamente 40% das neoplasias de cabeça e pescoço ocorrem na cavidade oral, constituindo cerca de 15% na faringe, 25% na laringe, e o restante nos sítios remanescentes, tais como glândulas salivares e tireoide (Stoeckli & Broglie, 2013). No Brasil, estimou-se 11.180 casos novos de câncer da cavidade oral em homens e 4.010 novos casos em mulheres para os anos de 2020-2022, sendo o 5º ou 6º tumor de maior incidência em homens, dependendo da região em território nacional, e 11º ou 12º tumor de maior incidência em mulheres (Estimativa 2020: Incidência de Câncer No Brasil, 2019.…”

Section: Carcinoma De Cabeça E Pescoçounclassified

Envolvimento da sinalização de NFkB no acúmulo de células-tronco tumorais em linhagens celulares de tumores de cabeça e pescoço resistentes à cisplatina

Castro¹

View full text Add to dashboard Cite

show abstract

“…Nos Estados Unidos, segundo a American Cancer Society, foram estimados 45.780 novos casos de câncer de boca e orofaringe e 8.650 mortes pela doença no ano de 2015 (Siegel et al, 2015). Segundo a International Conference of Innovative Aproaches in Head and Neck Oncology essa mesma lesão representa 4% de todas as neoplasias malignas na Europa (Stoeckli & Broglie, 2013) O CEC, dentre as lesões malignas, é a lesão mais frequente representando aproximadamente 90% dos casos (Chi et al, 2015). Muitas dessas lesões são precedidas por LPM (Nair et al 2012).…”

Section: Leucoplasia Verrucosa Proliferativaunclassified

Expressão de células dendríticas e células T em lesões potencialmente malignas e carcinoma espinocelular de boca

Pellicioli¹

View full text Add to dashboard Cite

show abstract

Recent innovations in head and neck oncology: a report from the ICHNO

Cited by 4 publications

References 8 publications

Electroporation in Head-and-Neck Cancer: An Innovative Approach with Immunotherapy and Nanotechnology Combination

Electroporation in Head-and-Neck Cancer: An Innovative Approach with Immunotherapy and Nanotechnology Combination

Envolvimento da sinalização de NFkB no acúmulo de células-tronco tumorais em linhagens celulares de tumores de cabeça e pescoço resistentes à cisplatina

Expressão de células dendríticas e células T em lesões potencialmente malignas e carcinoma espinocelular de boca

Contact Info

Product

Resources

About